Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Niraparib Maintenance for Recurrent Ovarian Cancer

July 14th 2017

Rucaparib for Recurrent Ovarian Cancer

July 14th 2017

Olaparib Maintenance for Recurrent Ovarian Cancer

July 14th 2017

When to Add Bevacizumab for Recurrent Ovarian Cancer

July 14th 2017

Secondary Debulking in Recurrent Ovarian Cancer

July 14th 2017

Key Considerations for Treating Recurrent Ovarian Cancer

July 14th 2017

Upfront Antiangiogenic Therapy in Advanced Ovarian Cancer

July 14th 2017

Optimizing Chemotherapy for Advanced Ovarian Cancer

July 14th 2017

Lymph Node Dissection for Ovarian Cancer

July 14th 2017

Somatic Mutation Testing for Ovarian Cancer

July 14th 2017

BRCA Testing in Ovarian Cancer

July 14th 2017

Therapy Combinations May Become the Treatment of Choice in Ovarian Cancer

July 12th 2017

The future of treatment for ovarian cancer may lie in immunotherapy combinations with PARP inhibitors or checkpoint inhibitors.

Dr. Levine on the PARP Inhibitor Landscape for Ovarian Cancer

July 7th 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the PARP inhibitor landscape for patients with ovarian cancer.

Study Offers Insight Into Age-Specific Breast, Ovarian Cancer Risk for BRCA-Positive Women

June 27th 2017

Researchers have yet to determine the degree to which harboring a BRCA1 or BRCA2 mutation raises a woman’s lifetime risk of developing breast and ovarian cancer.

Maintenance Rucaparib Improves PFS in Ovarian Cancer

June 20th 2017

Phase III data from the ARIEL3 trial showed that rucaparib (Rubraca) improved progression-free survival versus placebo as a maintenance treatment for women with platinum-sensitive, high-grade ovarian, fallopian tube, or primary peritoneal cancer.

Maintenance Olaparib Shows Promise in Platinum-Sensitive Serous Ovarian Cancer

June 16th 2017

The PARP inhibitor olaparib demonstrated clinically significant, long-term treatment benefits in patients with platinum-sensitive relapsed serous ovarian cancer in a recent study.

Ovarian Cancer Landscape Evolving With Encouraging SOLO2 Analyses, Novel Agents

June 13th 2017

Michael J. Birrer, MD, PhD, discusses some of the exciting data presented at the 2017 ASCO Annual Meeting, especially with olaparib (Lynparza) in SOLO2, and what other emerging advancements are poised to transform the landscape.

Mirvetuximab Soravtansine Shows Promise in Ovarian Cancer

June 12th 2017

Data from phase I pooled expansion cohorts showed that mirvetuximab soravtansine (IMGN853) induced a solid response rate in patients with platinum-resistant ovarian cancer who had received 1 to 3 prior lines of therapy.

Study Further Characterizes Niraparib PFS Benefit in Ovarian Cancer

June 9th 2017

Patients with ovarian cancer who had a partial response to previous platinum-based therapy had superior progression-free survival with or without germline BRCA mutations after treatment with niraparib (Zejula), according to a posthoc analysis of data from the ENGOT-OV16/NOVA trial presented at the 2017 ASCO Annual Meeting.

Update Sustains Olaparib/Cediranib PFS Benefit in Ovarian Cancer

June 9th 2017

In follow-up results to data first presented in December 2016, investigators found that the combination of olaparib (Lynparza) and cediranib maleate continued to show superior progression-free survival compared with olaparib alone for women with BRCA-negative recurrent platinum-sensitive ovarian cancer.